Partnering opportunity

A multifunctional linker for chimeric antigen receptor T-cells


A German university offers a new technology with application in cancer therapy. The researchers found that a human CD34 hinge region allows detection as well as rapid enrichment of successfully engineered chimeric antigen receptor (CAR) -expressing immune effector cells and reduces adverse side-effects. Industrial licensees are sought.

Partner sought

The German university offers licenses to biotechnology companies active in cancer research and immunotherapy The partners would have the rights to use the technology in their processes and do further therapeutic development.


Chimeric antigen receptors (CARs) have been developed for the molecular engineering of effector T-cells to be used in targeted cancer therapy. CARs consist of the antigen-binding single-chain fragment (scFv) of an antibody fused via a hinge region to a transmembrane domain (TM) and to one or more intracellular signalling co-stimulatory regions. CAR expressing T-cells are now able to specifically (and in a major histocompability complex-independent manner) recognize the corresponding tumor-associated antigens. The different scFv-regions determine the specifity and affinity of the CARs. Hundreds of different CARs have been generated with the clinically most successful so far being CAR constructs that recognize the B-cell-associated antigen CD19 on leukemias and lymphomas. The hinge region in CARs functions as a flexible spacer for the scFvs and improves the recognition/function of CARs for antigens closer located to the surface of target cells. For a large number of constructs, the hinge region consists of the CH2CH3 domain of a human IgG antibody. This can bind to Fcg-receptors on macrophages and other cells. The result is cross-activation and activation-induced cell death in vivo independent of recognition of the target antigen. Researchers of a German university have replaced the CH2CH3 site by fragments of the human CD34 antigen that contain the epitope for the CD34 antibody QBEND10 that is used in a device already available on the market. This exchange has decisive benefits: On the one hand unwanted immune side-effects are potentially prevented. On the other hand modified T cells can be easily detected using standard flow cytometry. Thus engraftment and persistence of transduced T-cells in vivo can be readily assessed. Ultimately, using this hinge domain, modified T-cells can easily and rapidly be selected and enriched by the available system for clinical use. By including this hinge region in CAR constructs for selection, common viral and also nonviral vectors for CAR transfer have sufficient space for the introduction of a safety switch that facilitates the use of allogeneic or even haploidential donor effector cells. The university seeks licensees with activities in the area of immunotherapy, who would like to implement the research results. Within this co-operation further therapeutic development is also possible.

Advantages and innovations

• More rapid and easy staining for follow-up of CARs • More rapid and easy isolation of successfully engineered CAR T cells • Not susceptible to Fcg‑receptor binding • Modular composition enables other modifications in the hinge region

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company